What is Cardiff Oncology, Inc. (CRDF) stock price today?

Cardiff Oncology, Inc. (CRDF) is currently trading at $1.06, down 2.75% today.

What is CRDF P/E ratio?

Cardiff Oncology, Inc.'s P/E ratio is -1.87. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CRDF return on equity (ROE)?

Cardiff Oncology, Inc.'s return on equity (ROE) is -103.08%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Cardiff Oncology, Inc.'s market cap?

Cardiff Oncology, Inc. has a market capitalization of $81.70M.

NASDAQ · Biotechnology

Cardiff Oncology, Inc. (CRDF) Stock

$1.06 -2.75% NASDAQ: CRDF Healthcare

Valuation

Metric	Value
Price	$1.06
Market Cap	$81.70M
P/E Ratio	-1.87
P/B Ratio	2.89
P/S Ratio	169.93
EPS (TTM)	$0.00
52-Week High	$4.56
52-Week Low	$0.76
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-103.08%
ROA	-107.29%
ROCE	-159.30%
Gross Margin	-4900.00%
Operating Margin	-4900.00%
Net Margin	-85.27%
Debt/Equity	0.02
Current Ratio	3.75

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$1.0M	$1.0M
Operating Profit	$-29.0M	$-40.0M	$-45.0M	$-49.0M	$-49.0M
Net Profit	$-28.0M	$-39.0M	$-41.0M	$-45.0M	$-46.0M
EPS	$-0.73	$-0.89	$-0.93	$-0.95	$-0.69
Op Margin	-8037.6%	-10337.3%	-9305.7%	-7123.1%	-8256.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$150.0M	$116.0M	$82.0M	$97.0M	$62.0M
Total Liabilities	$9.0M	$10.0M	$12.0M	$14.0M	$16.0M
Cash	$12.0M	$16.0M	$22.0M	$51.0M	$17.0M
Borrowings	$3.0M	$3.0M	$2.0M	$2.0M	$1.0M

Latest News

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital InvestorsHub · Jul 15, 2026 Cardiff Oncology to Raise $10 Million in Share, Warrant Sale MT Newswires · Jul 15, 2026 Cardiff Oncology Announces $10 Million Registered Direct Offering GlobeNewswire · Jul 15, 2026 Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? Insider Monkey · Jun 30, 2026 CRDF: Phase II Update; Survival Advantage Extended Zacks Small Cap Research · Jun 22, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-23.0M	$-34.0M	$-31.0M	$-38.0M	$-38.0M
Investing Cash Flow	$-132.0M	$37.0M	$36.0M	$14.0M	$1.0M
Financing Cash Flow	$1.0M	$0	$0	$0	$0
Net Cash Flow	$-119.0M	$4.0M	$5.0M	$30.0M	$-34.0M
Free Cash Flow	$-23.0M	$-35.0M	$-31.0M	$-38.0M	$-38.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.03
EV / EBITDA	-1.99
FCF Yield	-47.40%
Quick Ratio	3.30
Interest Coverage	0.00
Return 1Y	-80.01%
Return 3Y	-38.20%
Return 5Y	-84.82%

Ownership

Insiders Held5.91%

Institutions Held32.87%

Institutions Float Held34.94%

Institutional Holder	Shares	Report Date
Blackrock Inc.	3,981,387	2026-03-31
Vanguard Capital Management LLC	2,855,966	2026-03-31
Laurion Capital Management, LP	2,646,738	2026-03-31
Pfizer Inc	2,411,575	2026-03-31
Acorn Capital Advisors, LLC	1,762,084	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
APLTApplied Therapeutics, Inc.	$0.10	+0.00%	-0.24	$14.86M	0.00%
CRBPCorbus Pharmaceuticals Holdings, Inc.	$5.27	-4.01%	-0.95	$97.64M	0.00%
ELTXElicio Therapeutics, Inc.	$1.81	-2.16%	-0.89	$34.51M	0.00%
FBRX	$76.99	+0.00%	-4.26	$1.58B	0.00%
IPHAInnate Pharma S.A.	$1.79	+0.14%	-2.89	$168.32M	0.00%

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc. is led by CEO Mani Mohindru, employs 32 people, headquartered in US, publicly traded since 2004.

Cardiff Oncology, Inc. (CRDF) stock trades at $1.06 with a market capitalization of $81.70M. The stock is valued at a price-to-earnings (P/E) ratio of -1.87, price-to-book of 2.89, price-to-sales of 169.93. Over the past 52 weeks the stock has ranged between $0.76 and $4.56, and currently trades 76.8% below its 52-week high.

On profitability, Cardiff Oncology, Inc. generates a return on equity (ROE) of -103.08%, return on capital employed of -159.30%, an operating margin of -4900.00%, a net profit margin of -85.27%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides